Neurosense TherapeuticsNRSN
13F holders, Q1 2025 (March 31)11holders −2
2new positions
4sold out
$0.93avg. 13F price*
At the end of Q1 2025, 11 institutions reported holding Neurosense Therapeutics Ltd. (NRSN) in their 13F filings, down 2 from Q4 2024. 2 opened new positions and 4 sold out. The largest holders were Morgan Stanley ($47K), Meitav Investment House Ltd. ($37K) and XTX Topco Ltd ($31K).
- Company
- Neurosense Therapeutics Ltd.
- CUSIP
- M74240108
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $10K |
| Exits | 4 | $483K |
All 13F filers, Q4 2024 → Q1 2025: 11,985 shares bought and 463,606 shares sold, net −451,621 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Morgan Stanley | 0.00% | Reduce -50.8% | 50,501 | $47K |
| Meitav Investment House Ltd. | 0.00% | No change | 40,000 | $37K |
| XTX Topco Ltd | 0.00% | Reduce -19.6% | 33,706 | $31K |
| Commonwealth Equity Services, LLC | 0.00% | Add +6.2% | 17,250 | $16K |
| Geode Capital Management, LLC | 0.00% | No change | 15,870 | $15K |
| Two Sigma Securities, LLC | 0.00% | Reduce -2.1% | 14,705 | $14K |
| Warberg Asset Management LLC | 0.04% | No change | 10,700 | $10K |
| Hurley Capital, LLC | 0.01% | New | 8,710 | $8K |
| UBS Group AG | 0.00% | New | 2,275 | $2K |
| Cwm, LLC | 0.00% | No change | 1,000 | $1K |
| SBI Securities Co., Ltd. | 0.00% | No change | 175 | $163 |
"% of holder's portfolio" is NRSN's weight in each manager's 13F, not the share of Neurosense Therapeutics Ltd. the manager owns.